Aethlon Medical has reported positive results from two studies which revealed that its Hemopurifier demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.
In the lymphoma study, which was conducted at the City of Hope Cancer Research Hospital in California, exosomes derived from lymphoma patients were circulated through Aethlon Medical’s Hemopurifier.
The study results revealed that each sample confirmed a significant exosome capture rate, validating the use of Hemopurifier as a therapeutic for the treatment of lymphoma.
In a separate study, exosomes derived from colorectal cancer patients were also circulated through the company’s Hemopurifier.
The study results also confirmed significant exosome capture rate and validated the use of Hemopurifier as a therapeutic for this colorectal cancer.
Aethlon Medical has reported that Exosome Sciences, its wholly owned subsidiary, is developing its proprietary ELLSA assay that will enable researchers to identifyexosomes in blood and other fluids.
The Hemopurifier is a medical device which works by selectively targeting the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system.